




Introduction: Non insulin dependent diabetes mellitus is the most common type of diabetes. Genetic factors, lipid profi les, hypertension are po-
tential risk factors for diabetes mellitus. Adenosine binding cassette transporter proteins 1 (ABCA1) plays a role in cholesterol metabolism, especially 
high density lipoprotein (HDL-cholesterol). There are multiple mechanisms by which HDL-cholesterol can be atheroprotective, it is clear that the 
relative activity of ABCA1 plays a major role. We aimed to investigate association of ABCA1 C69T gene polymorphism with lipid levels in Turkish type 
2 diabetic patients.
Materials and methods: After isolation of DNA by ethanol precipitation we determined ABCA1 gene polymorphism by using polimerase chain re-
action - restriction fragment lenght polymorphism (PCR-RFLP) method in 107 type 2 diabetic patients and 50 healthy controls.
Results: We have observed that the frequency of TT genotype is signifi cantly higher in healthy controls compared to patients (14% vs. 3%; P = 
0.008). Also frequency of T allele was higher in controls than in patients (34% vs. 21%; P = 0.020; OR (95% CI) = 0.52 (0.30-0.88)). There was no 
association of lipid levels and ABCA1 C69T polymorphism subgroups.
Conclusion: We have found signifi cantly higher frequency of both T allele and genotype in control group when compared to patients that made us 
think that T allele may be a protective factor against diabetes mellitus. But, we could not fi nd a relationship between genotypes and lipid concentra-
tions in our two groups. Larger studies will help us to understand the relationship between ABCA1 C69T genotype and lipid parameters in diabetes 
mellitus.
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Introduction
Type 2 diabetic patients exhibit dyslipidemia with 
high triglyceride and low high density lipoprotein 
(HDL-cholesterol) concentration which are the un-
derlying pathology behind cardiovascular disease 
(1,2). Numerous population studies have shown an 
association between plasma lipid levels and coro-
nary artery disease risk (3,4). Moreover, epidemio-
logical studies suggest that the risk of developing 
coronary heart disease for patient with diabetes 
mellitus is 2–4 times higher than their counter-
parts without diabetes (1). Some experimental 
studies suggested that accumulation of cholester-
ol in islets causes to reduced glucose-stimulated 
insulin secretion (GSIS), and impaired glucose tol-
erance in mice. Therefore elevated cholesterol lev-
els may be a risk factor for glucose intolerance and 
diabetes (5).
Adenosine binding cassette transporter proteins 1 
(ABCA1) plays a role in cholesterol metabolism, es-
pecially HDL-cholesterol. Previous investigations 
showed that homozygous mutations in the ABCA1 
gene cause Tangier disease and heterozygosity 
causes for familial hypoalphalipoproteinemia. 
There are multiple mechanisms by which HDL-
cholesterol can be atheroprotective, it is clear that 
the relative activity of ABCA1 plays a major role. 
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Genetic and molecular biology studies have sug-
gested that low plasma HDL-cholesterol concen-
tration in many individuals refl ect an impaired AB-
CA1 pathway, which would also promote the accu-
mulation of cholesterol in tissue macrophages. Al-
brecht et al. showed that ABCA1 gene expression 
was signifi cantly elevated in atherosclerotic 
plaques (6). Porchay et al. suggested that ABCA1 
gene polymorphisms modulate HDL-cholesterol 
concentrations in an interaction with body mass 
index (BMI), and thus, they might infl uence cardio-
vascular risk in the general population (7). In addi-
tion, ABCA1 R230C polymorphism was shown to 
be associated with a 4-fold occurrence of diabetes 
and it may have an important role in maintaining 
glucose-mediated insulin secretion (8). Salinas et 
al. reported that the absence of ABCA1 led to cho-
lesterol accumulation within the beta cell plasma 
membrane, suggesting that ABCA1 may be not 
only a determinant of HDL-cholesterol but also a 
link among diabetes, metabolic syndrome and 
atherosclerosis (9). In another study, the authors 
have demonstrated that high glucose can sup-
press the mRNA expression of ABCA1 in mouse 
primary peritoneal macrophages (10).
There were fewer investigations about the role of 
ABCA1 C69T polymorphism (rs1800977) in lipid re-
lated disorders such as diabetes, cardiovascular 
disease etc. According to these knowledge, we 
aimed to investigate the relationship between AB-
CA1 C69T gene polymorphisms and lipid concen-
trations in Turkish type 2 diabetic patients.
Materials and methods
Study design and subjects
Our investigation was a case-control study.
The patient group consisted of 107 patients (me-
dian = 56 years; min-max = 25-85 years; 71 females 
and 36 males) with type 2 diabetes. The patients 
were recruited from Department of Internal Medi-
cine, Haseki Training and Research Hospital be-
tween in the period from 2009 to 2011. Patients 
were diagnosed with diabetes mellitus based on 
the fasting blood glucose concentration (> 7 
mmol/L) (11). Systemic arterial hypertension was 
considered to be present if the SBP was > 130 mm 
Hg and/or DPB was > 90 mm Hg.
The control group was selected from patients at-
tending the general surgery and orthopedic clin-
ics of the same hospital and who were treated for 
trauma. BMI (weight in kilograms divided by the 
square of the height in meters) values were calcu-
lated retrospectively and categorized according to 
World Health Organization recommendations (12). 
The smoking status of an individual was assigned 
‘yes’ if they were smoking currently or had given 
up < 3 months previously. The control group was 
selected from patients without type 2 diabetes 
and with negative family history of diabetes melli-
tus. It consisted of 50 individuals (median = 49 
years; min-max = 29-85 years; 17 females and 33 
males).
This study was approved by the Ethical Committee 
of Istanbul University, The Istanbul Faculty of Med-
icine. All of participants, after giving written in-
formed consent, completed a structured question-
naire in order to collect demographic data.
Determination of biochemical parameters
After overnight fasting, blood samples were drawn 
in plain tubes (Vacuette, Greiner Labor technik, 
Germany). One plain tube was used for each sub-
ject. The samples were centrifuged for 10 min at 
1,500 × g at room temperature, followed by the re-
moval of serum. Serum was stored at -20 °C, until 
concentrations of triglycerides, total cholesterol 
and fasting blood glucose were determined by us-
ing Hitachi 717 autoanalyzer (Tokyo, Japan). Con-
centrations of HDL-cholesterol were measured 
subsequently after precipitation of ApoB-contain-
ing lipoproteins with phosphotungstic acid/MgC12. 
LDL-C concentration was calculated using the 
Friedewald formula when the triglyceride concen-
tration was < 4 mmol/L; otherwise, LDL-C concen-
tration was measured directly using the Hitachi 
717 autoanalyzer (Tokyo, Japan) (13,14).
Isolation of DNA
Blood specimens were collected in tubes contain-
ing EDTA (Vacuette, Greiner Labor technik, Germa-
ny) and DNA was prepared from the leukocyte pel-
lets by sodium dodecyl sulphate lysis (Sigma 
Aldrich, Taufkirchen, Germany), ammonium ace-
tate (Sigma Aldrich, Taufkirchen, Germany) extrac-
tion and ethanol (Sigma Aldrich, Taufkirchen, Ger-
many) precipitation (15). One tube containing 
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EDTA was used for each subject. DNA samples 
were stored at +4 °C until PCR application.
Determination of ABCA1 C69T gene
polymorphism
Gene polymorphisms were determined using fol-
lowing PCR-RFLP method (16). Template DNA (0.5-
1.0 µg) was used in a PCR under stringent condi-
tions to avoid the possibility of false positives for 
C69T genotyping. Reactions were performed with 
10 pmol of each primer (Invitrogen, Grand Island, 
USA): forward primer 5’ CAG CGC TTC CCG CGC 
GTC TTA 3’, reverse primer 5’CCA CTC ACT CTC GTC 
CGC AAT TAC 3’ in fi nal volume of 25 µL containing 
1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 
100 µmol/L of each dNTP (Invitrogen, Grand Island, 
USA) and 1 unit Taq Polymerase (Invitrogen, Grand 
Island, USA). Amplifi cation was carried out in a 
DNA Thermal Cycler (Applied Biosystems, Carlsbad, 
USA) for 33 cycles with denaturation steps at 94 °C 
for 1 minute, annealing at 60 °C for 1 minute and 
extension at 72°C for 2 minutes. PCR products 
were separated on 2% agarose gel and DNA was 
visualized by ethidium bromide (Invitrogen, Grand 
Island, USA) staining. Presence of the polymor-
phisms was determined by enzymatic digestion of 
the initial PCR product with BsmAI (Invitrogen, 
Grand Island, USA) at 37 °C for 2h. Three genotypes 
could be determined after electrophoresis: geno-
type CC (345 bp band), genotype TT (310 bp band) 
and genotype CT (both bands).
Statistical analysis
Allele and genotype frequencies were determined 
by direct counting. Categorical variables such as 
genotypes and alleles were compared using Chi-
Square (χ2) test and z-test. Diff erences in continu-
ous variables between carriers and control sub-
jects were tested using Student’s t test, except for 
creatinine, which was not normally distributed. 
Diff erences in creatinine and continuous outcome 
variables between carriers and control subjects 
were tested using the nonparametric Mann-Whit-
ney U test (17).
Statistical analyses were performed with SPSS for 
Windows standard version 7.5 software (SPSS Inc, 
Chicago, USA). A P value of 0.05 was accepted as 
the threshold for defi ning statistical signifi cance.
Results
Demographic characteristics are summarized in 
table 1. Total cholesterol (P = 0.001), triglycerides (P 
= 0.001), LDL-cholesterol (P = 0.001), VLDL-choles-
terol (P = 0.001), systolic blood pressure (SBP) (P = 
0.001), diastolic blood pressure (DBP) (P = 0.001), 
fasting blood glucose (P = 0.001) and total choles-
terol/HDL- cholesterol levels (P = 0.001), body mass 
index (P = 0.003) and frequency of hypertension (P 
= 0.001) were higher in patients than in control 
subjects.
Frequencies of ABCA1 C69T polymorphism
Patient and control groups were in Hardy-Wein-
berg equilibrium for ABCA1 C69T genotypes (P = 
0.310 and P = 0.440 respectively).
Distributions of C69T genotypes and alleles in 
study groups are shown in table 2. We have ob-
served that the frequency of TT genotype is sig-
nifi cantly higher in healthy controls compared to 
patients (14% vs. 3%; P = 0.008). Also frequency of 
T allele was higher in controls than in patients (34% 
vs. 21%; P = 0.020; OR (95% CI) = 0.52 (0.30-0.88)).
Relationship between polymorphism and
plasma lipid levels
We could not fi nd any relationship between AB-
CA1 C69T genotypes and lipid profi les. No associa-
tion was found in HDL-cholesterol concentration 
according to the genotypes (Table 3).
Discussion
ABCA1 has an important role in the reverse trans-
port of cholesterol from peripheral tissues to the 
liver via HDL-cholesterol. Mutations in ABCA1 gene 
may induce several lipid transport defects of HDL-
cholesterol (18). Numerous of studies on the rela-
tionship between ABCA1 and diabetes mellitus 
have been done in recent times. Vergeer et al. 
showed that heterozygous carriers of ABCA1 muta-
tions displayed mild hyperglycemia with no diff er-
ence in insulin response after an oral glucose chal-
lenge compared with noncarriers of similar age, 
sex, and BMI (19). In another study, Patel et al. indi-
cated that ABCA1 expression and protein concen-
trations in leukocytes, as well as function in cul-
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Body mass index (kg/m2) 27.45 ± 5.00 25.20 ± 3.83 0.003
Smoking (%) 23.4 24 0.930
Hypertension (%) 71.4 28 0.001
SBP (mmHg) 135.87 ± 17.53 123.80 ± 19.57 0.001
DBP (mmHg) 84.50 ± 10.52 74.90 ± 13.11 0.001
Triacylglicerol (mmol/L) 1.96 ± 1.10 1.23 ± 0.39 0.001
Total cholesterol (mmol/L) 5.49 ± 1.50 3.94 ± 0.71 0.001
HDL- cholesterol (mmol/L) 0.97 ± 0.24 0.98 ± 0.36 0.903
LDL- cholesterol (mmol/L) 3.67 ± 1.38 2.46 ± 0.67 0.001
VLDL- cholesterol (mmol/L) 0.91 ± 0.51 0.57 ± 0.18 0.001
Total cholesterol/
HDL- cholesterol 6.03 ± 2.40 4.40 ± 1.42 0.001
Fasting blood glucose (mmol/L) 9.85 ± 3.76 5.29 ± 1.41 0.001
Urea (mmol/L) 6.86 ± 3.29 7.99 ± 4.27 0.387
Creatinine (µmol/L) 78.67 (69.61-91.93) 79.56 (68.51-91.71) 0.946
TABLE 1. Demographic characteristics of the study population.
ABCA1 C69T Patients(N = 107)
Controls
(N = 50) P OR 95%Cl
CC 65 (0.61) 23 (0.46)
CT 39 (0.36) 20 (0.40) 0.360* 0.69 0.34-1.42
TT 3 (0.03) 7 (0.14) 0.008* 0.15 0.04-0.64
C 169 (0.79) 66 (0.66)
0.020** 0.52 0.30-0.88
T 45 (0.21) 34 (0.34)
*Fisher exact test vs. CC genotype; **Chi-square test.
TABLE 2. Distribution of ABCA1 C69T genotypes and alleles in study groups.

























































































TABLE 3. Distribution of lipid levels according to ABCA1 C69T genotypes in study groups.
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tured skin fi broblasts, are reduced in type 2 dia-
betic patients (20). Brunham et al. reported that a 
new role for ABCA1 in mediating cholesterol 
homeostasis and insulin secretion in pancreatic 
β-cells. According to their results, ABCA1 was high-
ly expressed in β-cells, and absence of β-cell AB-
CA1 resulted in accumulation of cellular cholester-
ol, marked reduction in insulin secretion in vivo 
and a progressive impairment in glucose toler-
ance. This result gives us important information 
about ABCA1 genes and diabetes risk (5). Gao et al. 
showed that reduction in the concentration of 
HDL-C may be responsible for accelerated athero-
sclerosis in diabetic patients with poor glycemic 
control (10).
In previous studies, a lot of ABCA1 polymorphisms 
were investigated in lipid related diseases such as 
coronary artery disease and diabetes mellitus 
(21,22).
In a previously published study, recently found fre-
quent non-synonymous R230C variant within AB-
CA1 gene was associated with HDL-cholesterol 
concentration, obesity and type 2 diabetics in 
Mexican Mestizos. It was determined that cells ex-
pressing the C230 allele showed a 27% cholesterol 
effl  ux reduction confi rming that this variant has a 
functional eff ect in vitro. Also, C230 allele was as-
sociated with lower HDL-cholesterol concentration 
and higher body mass index (23). Harada et al. pro-
vided an evidence that the I/M 823 variant, not the 
R/K 219 variant, in the ABCA1 gene is a determinant 
of the HDL-cholesterol level. In addition, these au-
thors showed the importance of this gene on lipid 
metabolism in Japanese patients with CAD (24). 
Tregouet et al. found that the ABCA1 R219K variant 
is associated with myocardial infarction risk (25).
Liu et al. suggested that the -191 G/C SNP in the 
promoter region of the ABCA1 gene is associated 
with CAD (26). Hong et al. found that the ABCA1 
G2265 T variant may lead to decreased HDL-cho-
lesterol (27). Porchay-Baldérelli et al. observed that 
the M allele of the I883M SNP was associated with 
higher HDL-cholesterol concentration and also the 
minor allele of the +378GNC SNP was associated 
with lower HDL-cholesterol concentration in 3129 
French people (28). Saleehen et al. found a novel 
mutation in ABCA1 gene associated with low HDL-
cholesterol concentration and type 2 diabetes 
mellitus (29).
In current study we have investigated ABCA1 C69T 
polymorphism in type 2 diabetic patients. Accord-
ing to the previous studies, our fi rst aim was to ex-
plore possible relationship between ABCA1 C69T 
polymorphism and lipid concentrations in diabetic 
patients. However, we did not fi nd any relationship 
between lipid levels and C69T gene polymorphism 
in both study groups. Whereas, in our previous 
study, we observed that the C69T polymorphism 
was associated with HDL-cholesterol concentra-
tion (30). In another Turkish study, Hodoglugil et al. 
evaluated polymorphisms in the ABCA1 gene in 
Turks, which is a population characterized by low 
HDL-cholesterol concentration. They observed 
that rare alleles of the C14T and V771M polymor-
phisms were associated with higher HDL-choles-
terol concentration in men (31).
However, similarly to our results, some studies 
have reported no association between ABCA1 pol-
ymorphisms and lipid profi le. Finnish Study sug-
gested that the ABCA1 locus was not linked to HDL-
cholesterol concentration in the coronary heart 
disease (32).
Nevertheless, we have found signifi cantly higher 
frequency of both T allele and genotype in control 
group when compared to patients that made us 
think that T allele may be a protective factor 
against diabetes mellitus. But, we could not a rela-
tionship between genotypes and lipid concentra-
tions in our two groups.
The present study has some potential limitations, 
the small number of study groups being the most 
important one. This could be a reason for some of 
the results that demonstrated no statistical signifi -
cance. Studies with a larger sample size in diff er-
ent races will help us to understand relationship 
between ABCA1 C69T polymorphism and lipid pa-
rameters in diabetes mellitus.
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Ispitivanje polimorfi zma ABCA1 C69T kod bolesnika sa šećernom bolesti tipa 2
Sažetak
Uvod: Šećerna bolest tipa 2 najčešći je tip šećerne bolesti. Genetski faktori, lipidni status i povišeni krvni tlak predstavljaju potencijalne čimbeni-
ke rizika za razvoj šećerne bolesti. Adenozin-trifosfat vezujući kasetni protein (engl. adenosine binding cassette transporter proteins 1, ABCA1) ima 
ulogu u metabolizmu kolesterola, a posebno kod HDL-kolesterola. Postoje višestruki mehanizmi kojim HDL kolesterol može predstavljati zaštitu 
od stvaranja plaka te je jasno da pritom relativna aktivnost ABCA1 igra veliku ulogu. Naš je cilj bio istražiti povezanost polimorfi zma ABCA1 C69T s 
koncentracijom lipida kod Turskih bolesnika oboljelih od šećerne bolesti tipa 2.
Materijali i metode: Nakon izolacije DNA metodom taloženja u etanolu, polimorfi zam C69T gena ABCA1 određen je kod 107 ispitanika oboljelih 
od šećerne bolesti tipa 2 i 50 zdravih ispitanika primjenom metode lančane reakcije polimerazom – polimorfi zma restrikcijskih fragmenata na 
osnovi njihove duljine (engl. polimerase chain reaction- restriction fragment lenght polymorphism, PCR-RFLP).
Rezultati: Istraživanje je pokazalo da je učestalost TT genotipa statistički značajno viša kod kontrolnih ispitanika u usporedbi sa skupinom bole-
snika (14% vs. 3%; P = 0,008). Također, frekvencija T alela bila je viša kod kontrolnih ispitanika nego kod ispitanika sa šećernom bolesti (34% vs. 
21%; P = 0,020; OR (95% CI) = 0,52 (0,30-0,88)). Nije bilo povezanosti između koncentracije lipida i polimorfi zma ABCA1 C69T.
Zaključak: Pronašli smo visoke učestalosti T alela i TT genotipa kod kontrolne skupine u usporedbi s bolesnicima sa šećernom bolesti, što nas na-
vodi na zaključak da je T alel protektivan čimbenik za šećernu bolest. Međutim, nismo mogli naći vezu između genotipova i koncentracije lipida u 
naše dvije skupine ispitanika. Daljnja će istraživanja pomoći u razumijevanju veze između genotipa ABCA1 C69T i lipidnih parametara kod šećerne 
bolesti.
Ključne riječi: šećerna bolest; lipoproteini; lipoprotein visoke gustoće; dislipidemija; genetski polimorfi zam
